Fresenius Medical Care AG (FMCQF) EBITDA (2009 - 2026)

Fresenius Medical Care AG has reported EBITDA for 18 years, with the latest figure at $541.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 40.28% year-over-year to $541.5 million in Q2 2026; TTM through Jun 2026 was $3.3 billion, a 6.26% decrease from a year earlier, with the FY2025 full-year figure at $3.9 billion, up 15.6% from the prior year.
• EBITDA was $541.5 million for Q2 2026 at Fresenius Medical Care AG, down from $876.9 million in the prior quarter.
• The five-year high for EBITDA was $1.3 billion in Q4 2025, with the low at $541.5 million in Q2 2026.
• Average EBITDA over 5 years is $861.0 million, with a median of $867.9 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: EBITDA surged 40.6% in 2025, then tumbled 40.28% in 2026.
• Over 5 years, EBITDA stood at $937.6 million in 2022, then decreased by 2.0% to $918.9 million in 2023, then rose by 2.81% to $944.6 million in 2024, then surged by 40.6% to $1.3 billion in 2025, then sank by 59.23% to $541.5 million in 2026.
• The last three EBITDA figures came in at $541.5 million (Q2 2026), $876.9 million (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.